Clinical trial NCT05417659: Glycogen and Appetite
Official title: The Effect of Suppression of Adipose Lipolysis on GLP-1 and Energy Intake in Men and Women
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Energy Intake
Lead sponsor: University of Bath
Sponsor class: OTHER
First posted: 2022-06-14
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: Obesity is the outcome of chronic excessive energy intake and reduced energy expenditure leading to energy imbalance. It is a risk factor for many preventable diseases such as metabolic disease and its consequences such as type 2 diabetes and cardiovascular disease. Sedentary adults have been shown to have an increased appetite in excess of energy requirements and adults who are more active are able to better regulate energy intake. It is thought that carbohydrate availability and specifically hepatic glycogen utilisation during exercise is a regulator of appetite. However, the majority of research so far does not support this theory, potentially due to research not examining the tissue-specific link between glycogen use and appetite. The aim of this study is to assess whether altering substrate utilisation during exercise by suppressing lipolysis influences GLP-1 levels and caloric intake post exercise. Additionally, the study will explore if there is a tissue specific link between substrate utilisation and post exercise energy intake and examine potential sex differences.


Eligibility criteria: Inclusion Criteria:

* Males aged 18-60 and premenopausal women
* Physically active (at least 30 minutes of exercise 3 times a week)
* Body mass index 18.0-30.0 kg·m-2

Exclusion Criteria:

* Weight instability (\>5kg change in body mass over last 6 months)
* Restrained eater (e.g. limiting food intake, calorie counting)
* Current smoker
* Aversion or allergy to test meal foods
* Pregnant or lactating
* Amenorrhoea in women
* Any medical condition or medication that could introduce bias into the study (e.g., diabetes, CVD, lipid or glucose metabolism altering medications)
* Any cardiopulmonary condition prohibiting exercise testing
* Any contraindication to niacin or aspirin (e.g., diabetes, gout, clotting disorders, allergy to non-steroidal anti-inflammatory drugs)

Primary outcomes:
measure: Difference in ad libitum energy intake
timeFrame: 2 hours post exercise
Secondary outcomes:
Other outcomes:
measure: Change in plasma GLP-1 concentrations post exercise
timeFrame: 2 hours
measure: Change in plasma leptin concentrations post exercise
timeFrame: 2 hours
measure: Change in plasma insulin concentrations during exercise
timeFrame: 1 hour
measure: Change in plasma non-esterified fatty acid concentrations during exercise
timeFrame: 1 hour
measure: Change in plasma glucose concentrations during exercise
timeFrame: 1 hour
measure: Change in plasma lactate concentrations during exercise
timeFrame: 1 hour
measure: Change in carbohydrate oxidation during exercise
timeFrame: 1 hour
measure: Change in fat oxidation during exercise
timeFrame: 1 hour
measure: Change in skin temperature during exercise
timeFrame: 1 hour
measure: Change in core body temperature during exercise
timeFrame: 1 hour
measure: Muscle glycogen utilisation
timeFrame: 1 hour
measure: Extra-muscular glycogen oxidation
timeFrame: 1 hour
measure: Difference in blood pressure between conditions
timeFrame: 3 hours
Locations:
city: Bath
country: United Kingdom
facility: Department for Health, University of Bath
Study officials:
References: